Last updated on January 2018

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers


Brief description of study

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Renal, Colorectal and GBM Cancers

Detailed Study Description

A Phase 1 & 2 Study of the Safety, Tolerability and Efficacy of Varlilumab Administered in Combination With Nivolumab in Advanced Refractory Solid Tumors (Head and Neck, Renal and others).

Eligible patients will be enrolled and receive varlilumab in combination with nivolumab (Opdivo).

All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.

Clinical Study Identifier: TX147785

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )